- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02893865
Evolution of Oxidative Stress in Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure (CardioX SAS)
Published data indicate that obstructive sleep apnea syndrome (OSAS) worse the prognosis of coronary artery disease (CAD) and that oxidative stress can link this 2 diseases.
Investigators hypothesise that oxidative stress decrease after 3 months of continuous positive airway pressure (CPAP) in this specific population.
The results may have major implication in the comprehension of physiopathologic processes linking OSAS and CAD and in the treatment of OSAS in this specific population.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by recurrent upper airway collapse during sleep and has been associated with worsened prognosis in patients with coronary artery disease (CAD). Moderate OSAS can be defined by an apnea hypopnea index (AHI) between 15 and 30 events/hour.
Pathophysiologic processes are complex and it seems that oxidative stress play and important role. Studies showed that continuous positive airway pressure (CPAP) influence oxidative stress but the results are conflicting.
Moreover there are uncertainties whether diagnosing and treating OSAS can influence the pathophysiological and clinical outcomes in patients with CAD.
Therefore, we aim to test the effects of 3 months of CPAP on systemic redox balance evaluated by plasma GSH/GSSG ratio.
Patients with moderate OSAS will be randomized for the intervention.
Patients with AHI <15/h or >30/h will be included in an ancillary study (blood and urinary test, MIBG scintigraphy) to characterize the biological profile of coronary patients based on their AHI.
For a alpha threshold of 5% and a study power of 80%, the study should include 16 patients in each group. Taking in account a possible 20% of dropout the study will need to include 20 patients by randomized arm to demonstrate an effect.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Montpellier, Frankrijk, 34295
- CHU of MONTPELLIER
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Apnea Hypopnea Index 15-30/h
- Stable Coronary artery disease
- Obligation of obtaining informed consent form
Exclusion Criteria:
- Heart failure with LVEF less than or equal to 45%
- Other Chronic disease: renal failure, COPD Index - central apneas than or equal to 50% of the total IAH
- treatment with CPAP or mandibular advancement device
- IMC> 40 kg / m²
- Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins ...).
- Treatment with allopurinol or N-acetylcysteine, in the 4 weeks preceding the study.
- PaCO2> 45 mmHg - Counter-indication to the use of PPC: bullous lung disease, pathological hypotension, bypass airway, pneumothorax, signs of sinus infections or inner ear
- Exclusion period on subject compared to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached.
- Participation of the subject to another study.
- Not affiliated with a social security scheme subject or not the beneficiary of such a regime.
- Pregnant or breastfeeding women, patient unable to give consent, protected adult, vulnerable
- Subject deprived of liberty by judicial or administrative decision
- HIV infection, hepatitis B or hepatitis C known
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Experimental
Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
|
Continuous positive airway pressure treatment during three months with adherence recording
|
Sham-vergelijker: Sham Comparator
Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
|
Sham-continue positieve luchtwegdruk gedurende drie maanden met registratie van therapietrouw
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage change of serum GSH/GSSG ratio
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
Blood test
|
at the inclusion and the end (3 months) of the study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change, after 3 months, of the SOD (parameter of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the catalase (parameters of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the Vit C and E (parameters of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the isoprostanes (parameter of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the 8OHDG (other parameters of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
by blood test
|
at the inclusion and the end (3 months) of the study
|
Change, after 3 months, of the GPX (parameter of serum oxidative stress level)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the inflammation parameters: IL6, IL8, TNF α (blood test)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the urinary catecholamines by urine test
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the MIBG scintigraphy
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the endothelial function (endoPat)
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the blood pressure
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
24h ambulatory blood pressure monitoring
|
at the inclusion and the end (3 months) of the study
|
Change, after 3 months, of the quality of life by the SF 36 questionnaire
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the quality of sleep by PSQI questionnaire
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the sleepiness by the Epworth scale
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
|
Change, after 3 months, of the physical activity by the Voorips questionnaire
Tijdsspanne: at the inclusion and the end (3 months) of the study
|
at the inclusion and the end (3 months) of the study
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Hartziekten
- Hart-en vaatziekten
- Vaatziekten
- Ziekten van het zenuwstelsel
- Ziekten van de luchtwegen
- Arteriosclerose
- Arteriële occlusieve ziekten
- Ademhalingsstoornissen
- Slaapstoornissen, intrinsiek
- Dyssomnieën
- Slaap-waakstoornissen
- Ziekte
- Tekenen en symptomen, ademhaling
- Coronaire hartziekte
- Myocardiale ischemie
- Hart-en vaatziekte
- Slaapapneusyndromen
- Syndroom
- Apneu
Andere studie-ID-nummers
- UF 9542
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Coronaire hartziekte
-
Lawson Health Research InstituteVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftCanada
-
Deutsches Herzzentrum MuenchenVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftDuitsland
-
University Hospital, AngersWervingPopliteale slagaderbeknellingFrankrijk
-
University Hospital, AngersVoltooidPoplitea Entrapment SyndroomFrankrijk
-
Stanford UniversityIngetrokkenPoplitea Artery Entrapment Syndroom | Functioneel beknellingssyndroom van de arteria popliteaVerenigde Staten
-
University Hospital, Strasbourg, FranceWervingEpistaxis, Anterior Ethmoid ArteryFrankrijk
-
Resicardunion nationale de formation et d'evaluation en medecine cardio-vasculaireVoltooidHartfalen | Acute kransslagader syndroom | Coronaire Bypass Graft Stenose van Native Artery GraftFrankrijk
Klinische onderzoeken op Sham-continue positieve luchtwegdruk
-
Ottawa Hospital Research InstituteVoltooidHypertensie | Diabetische nefropathie | Type 2 diabetes | SlaapapneuCanada
-
Bangladesh University of Engineering and TechnologyDhaka Medical CollegeVoltooidCovid19 | HypoxemieBangladesh